{"id":"W4381885413","doi":"10.1016/s0140-6736(23)01163-7","title":"Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial","year":2023,"lang":"en","type":"article","venue":"The Lancet","topic":"Diabetes Treatment and Management","field":"Medicine","cited_by":297,"is_retracted":false,"has_abstract":false,"ca_institutions":"LMC Diabetes & Endocrinology (Canada)","funders":"Steno Diabetes Center Copenhagen","keywords":"Semaglutide; Medicine; Type 2 diabetes; Clinical endpoint; Internal medicine; Randomized controlled trial; Adverse effect; Intention-to-treat analysis; Exenatide; Diabetes mellitus; Dulaglutide; Physical therapy; Liraglutide; Endocrinology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009937581,0.0003672389,0.001767949,0.0002255927,0.0000981308,0.0000449104,0.0002517246,0.00009552115,0.00008116021],"category_scores_gemma":[0.0002529821,0.0002194094,0.000155448,0.0006113921,0.0002216751,0.00009518943,0.00009500809,0.0002731339,0.00006200995],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009674313,"about_ca_system_score_gemma":0.0001320538,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005594705,"about_ca_topic_score_gemma":0.0001179443,"domain_scores_codex":[0.9975595,0.0002107925,0.0006708635,0.0004618595,0.0004226336,0.000674288],"domain_scores_gemma":[0.9977571,0.0009443787,0.0003341911,0.0007110697,0.00009081223,0.0001624977],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9809029,0.001235546,0.002064218,0.0001965404,0.001201683,0.00007896787,0.0009368568,0.00004472072,0.0009444864,0.0000809257,0.002754233,0.009559001],"study_design_scores_gemma":[0.9795802,0.003262362,0.005449585,0.0004365923,0.001069815,0.000001981897,0.0004909508,0.0008075427,0.001439485,0.00002444238,0.007195456,0.0002416337],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9842341,0.0004115718,0.00000537102,0.003289985,0.0002251755,0.007354131,0.00006023623,0.0001270896,0.00429233],"genre_scores_gemma":[0.9944367,0.000608164,0.0001912143,0.0003661142,0.000533263,0.0003947642,0.0002074725,0.00004882624,0.003213433],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01020264,"threshold_uncertainty_score":0.8947257,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05563561283814931,"score_gpt":0.33893580047556,"score_spread":0.2833001876374107,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}